西 (Gancao Xiexin) ACSL4

Zengfeng Pan1, Caiyan Gan1, Shaobin Zhi2

  • 1Institute of Basic Medical Sciences, Meizhou People's Hospital, Meizhou Academy of Medical Sciences, Meizhou, China; Guangdong Engineering Technological Research Center of Clinical Molecular Diagnosis and Antibody Drugs, Meizhou, China.

PubMed
概括

甘西 (GCXXD) 开制剂通过减少ferroptosis,一种涉及ACSL4.4.的细胞死亡途径来治疗性结肠炎 (UC). 这种传统的中医药保护了肠道屏障,缓解了UC的症状.